Introduction
Breast cancer is the most common neoplastic disease of women in the Western world with a lifetime risk of 11-12%. In spite of earlier detection and better treatment, this disease still accounts for the second largest number of cancer-related deaths in the West (Parker et al., 1997) . As with other cancer types, mortality and morbidity are consequences of invasive and metastatic behaviour of the transformed cells. Invasion and metastasis are associated with up-or downregulation of expression of a range of genes, including those encoding cell adhesion receptors and proteolytic enzymes (Meyer and Hart, 1998; Chang and Werb, 2001 ). Discovery of variation in gene expression associated with tumour progression may be useful for the development of novel therapies targeted against the protein products of such differentially expressed genes. For example, progression of malignant melanoma is often correlated with increased expression of integrin subunits by the melanoma cells (Marshall and Hart, 1996) , while synthetic Arg-Gly-Asp (RGD)-containing peptides, which disrupt integrin function, can inhibit melanoma invasion (Gehlsen et al., 1988) . Equally, the development of synthetic, low molecular weight inhibitors of matrix metalloproteinases (MMPs) as invasion inhibitors was based upon the observation that increased activity of such enzymes was associated with increased invasive/metastatic activity (Talbot and Brown, 1996) . However, it is clear that we still have limited knowledge regarding many of those changes in gene expression that underlie the conversion from carcinoma in situ to frankly invasive cancer. Global patterns of gene expression can now be determined relatively easily using microarray analysis (Schena et al., 1995) . Such technology has been used to determine differences between normal and neoplastic tissues, often at different stages of tumour progression (DeRisi et al., 1996; Perou et al., 1999; Nocito et al., 2001) , while other techniques of global analysis of gene expression have revealed differences between primary and secondary tumour deposits (Saha et al., 2001) . However, to the best of our knowledge, relatively little has been done in comparing transformed cells from within different parts of the same neoplastic mass. It seemed plausible to infer that the cancer cells at the border of a lesion would be more likely to be expressing, or repressing, genes that could be involved in invasive activity than those cells in the more central portions of the tumour mass. This could be so if the tumours were invasive or, as in the case of ductal carcinoma in situ (DCIS), might have potential to become invasive. Accordingly, in the present report we have microdissected the peripheral rim thickness of ducts containing DCIS, two to three cells deep and devoid of surrounding myoepithelial cells, and compared gene expression profiles of these cells with the expression profiles of cells from the central portion of the affected duct. Similarly, we have microdissected cancer cells from the infiltrating edge region of invasive cancer and cells from regions remote from the infiltrating rim of the carcinoma, and compared their gene expression patterns. Confirmation of some of these identified changes has been achieved using quantitative real-time PCR and immunohistochemistry. The work shows that tumour cells in discrete areas of a neoplastic mass, even though this might be quite small, may vary in relative levels of gene expression.
Results

Comparison of gene expression patterns of peripherally located cancer cells relative to centrally located tumour cells
The appearance of tissue before and after microdissection is illustrated in Figure 1 . A summary of the genes whose expression was altered consistently in three replicate experiments is presented in Tables 1 and 2 . These analyses revealed that, out of the 1176 genes examined in these studies, nine genes were upregulated (1.59-to 2.24-fold) in the periphery of DCIS lesions relative to the cellular expression in the central mass. Conversely, three genes were downregulated (0.34-to 0.58-fold) (Table 1 ). In the frankly invasive carcinomas, five genes were upregulated (1.23-to 3.96-fold) and four genes were downregulated (0.37-to 0.56-fold) (Table 2) . Interestingly, with one exception, neither upregulated nor downregulated genes were common to both tumour stages, possibly suggesting that invasive/infiltrative pathways may vary according to the stage of tumour development. The one gene showing a concordant pattern of expression in both DCIS and invasive cancer was the TSG101 tumour susceptibility gene, which was downregulated about threefold in the periphery (0.37 in invasive cancer and 0.34 in DCIS) of both lesions. An alternative interpretation could be that TSG101 expression was upregulated about threefold in the centre of these two lesions since adjacent normal tissue failed to stain for TSG101 protein (see later).
Quantitative real-time PCR
The distribution of transcripts for TSG101 and RhoC, which were altered or not altered, respectively, in the periphery of the DCIS and which were downregulated or upregulated, respectively, in the periphery of invasive cancers relative to the central region, confirmed the microarray analyses (see Tables 1 and 2 ). Thus RhoC, which was elevated 1.59-fold in the peripheral regions of invasive breast cancer, gave a 2.03 Taqman ratio (Tables  1 and 2 ). TSG101, which was downregulated in the periphery of both DCIS and invasive cancer, showed substantially reduced Taqman ratios of 0.48 and 0.13-0.25 (Tables 1 and 2 ).
Immunohistochemical staining
A total of 20 breast cancer cases, with representation of different tumour types and different clinical stages (11 cases of invasive ductal carcinoma, two grade I, three grade II and six grade III; and 16 cases of DCIS, three low nuclear grade, one intermediate nuclear grade and 12 of high nuclear grade), were stained. To verify that the changes in mRNA levels detected with the microarray analysis were reflected at the protein level, we performed immunohistochemistry using commercially available antibodies. Cytokeratin 19 (CK 19) was selected as a control, since its expression level was unchanged (data not shown) between peripheral and central regions in both types of lesions. TSG101 was selected as an example of a gene downregulated at the periphery (or upregulated in the centre) of both DCIS and invasive carcinoma, and elongation factor 1 alpha (EF-1 a) was chosen as an example of a gene upregulated at the infiltrating edge of invasive carcinoma. Expression of EF-1 a also was found to be upregulated in two of three experiments in DCIS (data not shown) and the immunohistochemistry presented confirmed this elevation. Both anti-EF-1 a and anti-TSG101 show cytoplasmic immunoreactivity.
Positive staining for TSG101 was observed in the epithelial component of all cases of DCIS and invasive carcinoma, while epithelium of normal ducts and lobules showed no, or very occasional weak, staining. Myoepithelial cells of both normal ducts and DCIS appeared negative. The periphery of invasive carcinoma showed obvious weaker staining relative to the centre in at least 4/11 cases, whereas in DCIS there was weaker staining in the outer two to three epithelial cell layers compared to the centre.
EF-1 a was positive in epithelial cells of normal ducts and lobules, DCIS and invasive carcinoma but was negative in myoepithelial cells, of either normal ducts or DCIS. In 5/11 invasive carcinomas there was stronger staining at the periphery compared to the centre, while in 10/16 DCIS cases there was stronger staining in the outer two to three cell layers compared to the centre. Figure 2 shows an example of these differences in staining distribution in DCIS.
Discussion
In the present study, we have combined microdissection and cDNA microarray analysis to try to identify changes in gene expression at the infiltrating edge of invasive ductal carcinoma and at the peripheral rim of DCIS. The synthesis of microarray probes usually requires at least 10 mg total or 2 mg messenger RNA and thus we have used the SMARTt technique, which allows the generation of array probes using RNA from as little as 100-1000 cells (or 0.1 mg tissue) and which maintains the relative representation of each transcript in the original sample (Zhumabayeva et al., 2001) .
Previous microdissection and global gene expression analyses have not often examined the question of changes in gene expression associated with invasion. Mariani et al. (2001) looked at mRNA expression profiles from glioblastoma cells at the tumour core and Arginine/serine-rich splicing factor 7; splicing factor 9G8 0.58 the invasive rim using differential display. One of the 50-60 cDNA bands differentially expressed, P311, was shown to be overexpressed by invading glioblastoma cells, which was in accord with the protein product being localized at focal adhesions (Mariani et al., 2001) . Likewise, the cancer invasion front has been shown to express activated prosurvival pathways in prostate cancer using reverse-phase protein microarrays (Paweletz et al., 2001) . However, no substantial effort has yet been made to compare changes in gene expression associated with the positioning of cancer cells at the tumour periphery. The present report shows the feasibility of this approach, although we have made no effort to be global in our analysis. Rather we have used a limited procedure as proof of principle to demonstrate that cancer cells, even within small lesions, may vary in their gene expression profile according to their location within the mass. It was only recently demonstrated that laser capture microdissection is sufficient to isolate nanogram quantities of high-quality RNA, which can be used to generate labelled target for hybridization to oligonucleotide expression arrays (Luzzi et al., 2001) . In comparable experiments, also intended to act as proof of principle for microdissection techniques, expression profiles of captured cells located within one cell diameter of each other (although in markedly different anatomical compartments) have been shown to vary substantially (Scheidl et al., 2002) . We now show that the applications of such a technique are not restricted to comparisons between the components of different tissues but can be applied to intralesional comparisons.
Since we compared morphologically similar tumour cells within a single tumour deposit, rather than comparing normal with transformed cells, we had anticipated obtaining relatively low-level changes in gene expression. That none of the candidate genes varied by much more than two-to threefold in their expression levels (Tables 1 and 2) was not, therefore, surprising. Some of the upregulated or downregulated genes, such as cyclin B1 and cyclin H, almost certainly represent variation in growth characteristics between the core and the peripheral regions of the tumour (Hall et al., 1994) , although we were careful to exclude areas of obvious ischaemia or necrosis. While great care was taken during microdissection, it was possible that among the predominant epithelial cells there were some admixed normal cells, which could account for some of the changes. Overall changes in expression patterns though may well represent some genuine invasion-associated genes, for example, vimentin, RhoC, EF-1 a and TSG101. RhoC already has been found to have increased expression in more motile, invasive and metastatic tumours (Suwa et al., 1998) , while vimentin upregulation ( Gene expression changes in breast cancer G Zhu et al and the identification of changes in mRNA levels on two out of three analyses could be taken as further validation of our approach. TSG101, a well-recognized tumour susceptibility gene, when inactivated by antisense RNA has been reported to induce fibroblasts to become metastatic in athymic mice, possibly indicative of a suppressive effect on malignant, as distinct from tumorigenic, behaviour (Li and Cohen, 1996) .
EF-1 a not only functions as a polypeptide elongation factor, an activity that might indicate the greater metabolic activity of peripheral tumour cells, but also is a well-characterized F-actin and microtubule-binding protein (Condeelis, 1995) . Interestingly, overexpression of EF-1 a already has been correlated with increased metastatic propensity (Edmonds et al., 1996) . Our finding that EF-1 a is upregulated slightly in the periphery of invasive cancer relative to the central mass (Table 2) and that a similar upregulation was observed in two out of three occasions with DCIS, and was evident in the immunohistochemistry (Figure 2) , may indicate that this gene does have a role to play in mediating invasive activity.
Currently, we are investigating whether some of the genes identified in this screen have an impact on the behaviour of cells in motility/invasion assays. However, this has not been the major goal of our present work. Rather the clear demonstration that changes in gene expression occur between the tumour core and the periphery (which appear to be matched by changes in protein expression) indicates that the approaches used here can be used in larger-scale analyses to determine a wide range of invasion-associated genes. Indeed such approaches may identify any genes whose expression may be regulated by the spatial positioning of the tumour cells within the cancer mass.
Materials and methods
Tissue specimens
Tissue obtained from breast cancer patients with full ethical approval was stored in the Breast Pathology Laboratory in Guy's Hospital. Snap-frozen samples from five cases of ductal infiltrating adenocarcinoma (all grade III) of the breast and another five cases of high nuclear grade DCIS (grade II, three grade III), which had been prepared immediately following surgical resection, were used to make up 10 mm-thick frozen sections, used for microdissection. Samples and sections always were kept at -701C until microdissected.
Microdissection
The PALM Laser-MicroBeam System (PALM, Mikrolaser Technologie GmbH, Germany) was used to microdissect frozen breast cancer tissue sections. This method allows the transfer of selected cells directly to a microfuge tube lid using the laser pressure catapulting (LPC) process, which avoids mechanical contact and thus captures clean samples (Schutze et al., 1998) . After cutting in a cryostat, the sections were mounted onto polyethylene foil, according to the manufacturer's instructions. Sections were stained with a modified H & E staining protocol in order to maintain the morphological quality required for accurate microdissection. Air-dried (5 min) sections were stained for 30 s at room temperature with Gill's haematoxylin and then washed in purified water. Eosin Y was then applied for 15 s before washing briefly in purified water and air-drying for 2 min. Following staining, the sections were kept at À701C until microdissection. Cancer cells from the periphery or from the centre of DCIS, or from the infiltrating edge or the central portions of invasive cancer lesions were microdissected separately but pooled into two separate aliquots (i.e. 'pooled periphery' and 'pooled central') in order to even out individual variability.
RNA preparation, cDNA probe synthesis and probe labelling Total RNA from microdissected cancer cells was isolated using TRIZOL reagent (Gibco-BRL, Life Technologies Inc., Frederick, MD, USA) following the manufacturer's protocol with glycogen as an RNA carrier. RQ1 RNase-free DNase (Promega Corporation, Madison, WI, USA) was used to remove genomic DNA contamination. The quantity of total RNA derived from about 5 Â 10 4 cells was approximately 150-200 ng. Following microdissection, total RNA was extracted from the sections left behind and the RNA quality was verified by electrophoresis through agarose gel and visualization with ethidium bromide (data not shown).
The Atlas SMART Probe Amplification Kit (Clontech, Palo Alto, CA, USA) was utilized for cDNA synthesis (Zhumabayeva et al., 2001) and PCR amplification following the manufacturer's instructions. Purified cDNA was then labelled with [a-33 P]dATP (10 mCi/ml, 3000 Ci/mmol; Amersham Pharmacia Biotech, UK) with the reagents and according to the protocol as supplied in the Atlas kit. Three independent triplicate experiments were performed by independently dissecting similar populations of cells in serial sections, repeating RNA isolation and microarray hybridization.
Microarray hybridization
Human Cancer 1.2 Array (Clontech, Palo Alto, CA, USA) nylon arrays, comprising sequences of 1176 known cancerassociated genes involved in cell adhesion, cell-cycle regulation and tumour suppressor genes and including negative control and housekeeping genes (http://www.clontech.com/Atlas/ genelists/), were used. Each microarray hybridization was performed with a pool of five samples, to attenuate the effect of biological heterogeneity between individual tumour samples. According to the manufacturer's specifications, the filters were hybridized overnight with 5 Â 10 6 c.p.m. 5 ml in ExpressHyb Hybridisation Solution (Clontech, Palo Alto, CA, USA) at 681C in a roller bottle incubator. Filters were then washed twice with 2 Â SSC/1% SDS and twice with 0.1 Â SSC/0.5% SDS at 681C for 30 min each. Filters were exposed for 5 days in phosphor storage cassettes and scanned in a phosphorimager (Molecular Dynamics, Sunnyvale, CA, USA).
Data analysis
Image analysis and quantitation were performed with Atlaslmage 2.0 software (Clontech, Palo Alto, CA, USA), designed specifically for Atlas Arrays. After grid assignment, subtraction of background and global normalization were performed. Genes were considered to be expressed if the pixel intensity obtained after hybridization was more than twice the background level, and a 1.5-fold (0.66) difference was taken as the cutoff for scoring upregulated (or downregulated) expression. When the pixel intensity for a particular gene was more than twice the background on one filter and less than twice the background on the other, the ratio could not be calculated and the difference in intensity values was calculated instead. A difference with a negative value represents a gene downregulated in the tumour periphery. Comprehensive information about all the genes on particular arrays can be found at Clontech's AtlasInfot Bioinformatics Database (atlasinfo.-clontech.com).
Immunohistochemistry
Paraffin sections (3 mm), cut from a representative block from the primary tumour, were mounted on Vectabond (Vector Laboratories, Peterborough, UK)-coated slides. The sections were allowed to dry at 371C overnight prior to dewaxing. If necessary, antigen retrieval was performed by treatment in a pressure cooker for 2 min in 0.01 m citrate buffer, pH 6.0 (antigen retrieval was not necessary for TSG101). Following thorough washing in 0.015 m TBS (pH 7.6) and blocking with 20% normal rabbit serum, appropriate antibodies (anti-EF-1 a: Upstate Biotechnology, NY, USA; anti-TSG101: GeneTex, San Antonio, TX, USA; anti-CK 19: Dako Ltd., Copenhagen, Denmark) at 1 : 200, 1 : 100 and 1 : 50, respectively, were applied for 1 h. Sites of antigen-antibody binding were detected using biotinylated rabbit anti-mouse Ig followed by peroxidase conjugated streptavidin-biotin complex (both from Dako Ltd., Copenhagen, Denmark). Peroxidase activity was demonstrated using DAB. Sections were counterstained lightly with haematoxylin prior to dehydration, clearing and mounting. Sections were studied using light microscopy and evaluated independently by three observers (GZ, CD, IRH) for differences in distribution between centre and periphery of both DCIS and invasive carcinoma using the following scores: ++ ¼ strong difference; + ¼ moderate difference; 7 ¼ weak difference; À ¼ no difference. Results presented are based on the average scores from the analyses.
Quantitative real-time PCR
Two genes, TSG101 and RhoC, were selected for validation using quantitative real-time PCR and the analysis was conducted on SMARTt-PCR amplified cDNA (15 cycles) derived from the same RNA samples used in the microarray study.
TSG101 (Genebank accession number U82130) and RhoC (Genebank accession number L25081) primers and probe were designed using Primer Express software (PE-ABI; version 1.6). TSG101: forward primer: CCTCCCAATCCCAGTGGTTA, probe: CCAGGCTGTCCTTACCCACCTGGTG (5 0 -6-carboxyfluorescein-2 0 -6-carboxytetramethylrhodamine), reverse primer: ACTTGTTGTGGCAGGATATGGA. RhoC: forward primer: GAGCTGGCCAAGATGAAGCA, probe: ATGT-CCCGGCCTTCCTCAGACCG, reverse primer: CAAGG-TAGCCAAAGGCACTGA. The probes were labelled at the 5 0 end with 6-carboxy fluorescein (FAM; reporter) and at the 3 0 end with 6-carboxy-tetramethyl rhodamine (TAMRA; quencher). Primers and probes were stored at À201C until use. The housekeeping gene 18S rRNA was evaluated in all samples as internal control. The Taqman assay (Perkin-Elmer Applied Biosystems) utilizes the 5 0 -nuclease activity of the DNA polymerase (e.g. Taq or Tth polymerase) to hydrolyze a hybridization probe bound to its target amplicon.
In a total volume of 25 ml, the following was added as reaction mixture: 12.5 ml of TaqMan Universal Master Mix (Applied Biosystems), 2.5 ml of human 18S rRNA Assay Reagents (predeveloped; Applied Biosystems), 100 ng of cDNA, 300 nm of both forward and reverse primer for TSG101 or RhoC, 175 nm of probe for TSG101 or RhoC, and DEPC water to make up a total volume of 25 ml. PCR conditions were as follows: after 2 min at 501C, denaturation was performed at 951C for 10 min; PCR was carried out for 40 cycles with denaturation at 951C for 15 s and annealing at 601C for 1 min. The threshold cycle (C t ) for each sample was determined. The experiments were repeated at least twice for each sample to determine consistency of results. Reactions were recorded and analysed with the ABI7700 Prism Sequence detection system (Perkin-Elmer Applied Biosystems, Warrington, UK). Calculation of fold differences was performed as detailed previously (Van Trappen et al., 2001) .
Abbreviations CK 19, cytokeratin 19; DCIS, ductal carcinoma in situ; EF-1 a, elongation factor 1 alpha; TSG101, tumour susceptibility gene 101.
